These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 16153132)
1. Economic implications of biological therapies for Crohn's disease: review of infliximab. Bodger K Pharmacoeconomics; 2005; 23(9):875-88. PubMed ID: 16153132 [TBL] [Abstract][Full Text] [Related]
2. Maintenance of remission in Crohn's disease: current and emerging therapeutic options. Brookes MJ; Green JR Drugs; 2004; 64(10):1069-89. PubMed ID: 15139787 [TBL] [Abstract][Full Text] [Related]
3. Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn's disease. Yu AP; Johnson S; Wang ST; Atanasov P; Tang J; Wu E; Chao J; Mulani PM Pharmacoeconomics; 2009; 27(7):609-21. PubMed ID: 19663531 [TBL] [Abstract][Full Text] [Related]
4. Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis. Siddiqui MA; Scott LJ Drugs; 2005; 65(15):2179-208. PubMed ID: 16225377 [TBL] [Abstract][Full Text] [Related]
5. Cost-utility analysis of biologic treatments for moderate-to-severe Crohn's disease. Tang DH; Armstrong EP; Lee JK Pharmacotherapy; 2012 Jun; 32(6):515-26. PubMed ID: 22528603 [TBL] [Abstract][Full Text] [Related]
6. The cost-effectiveness of infliximab in Crohn's disease. Smart C; Selinger CP Expert Rev Pharmacoecon Outcomes Res; 2014 Oct; 14(5):589-98. PubMed ID: 25138162 [TBL] [Abstract][Full Text] [Related]
7. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies. Magro F; Portela F BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228 [TBL] [Abstract][Full Text] [Related]
8. Mild to moderate Crohn's disease: still room for step-up therapies? Bar-Meir S Dig Dis; 2009; 27(3):347-50. PubMed ID: 19786763 [TBL] [Abstract][Full Text] [Related]
9. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis. Keating GM; Perry CM BioDrugs; 2002; 16(2):111-48. PubMed ID: 11985485 [TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease. Loftus EV; Johnson SJ; Yu AP; Wu EQ; Chao J; Mulani PM Eur J Gastroenterol Hepatol; 2009 Nov; 21(11):1302-9. PubMed ID: 19465858 [TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis. Hazlewood GS; Rezaie A; Borman M; Panaccione R; Ghosh S; Seow CH; Kuenzig E; Tomlinson G; Siegel CA; Melmed GY; Kaplan GG Gastroenterology; 2015 Feb; 148(2):344-54.e5; quiz e14-5. PubMed ID: 25448924 [TBL] [Abstract][Full Text] [Related]
12. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease--modelling outcomes in active luminal and fistulizing disease in adults. Lindsay J; Punekar YS; Morris J; Chung-Faye G Aliment Pharmacol Ther; 2008 Jul; 28(1):76-87. PubMed ID: 18410558 [TBL] [Abstract][Full Text] [Related]
13. Economic impact of combination therapy with infliximab plus azathioprine for drug-refractory Crohn's disease: a cost-effectiveness analysis. Saito S; Shimizu U; Nan Z; Mandai N; Yokoyama J; Terajima K; Akazawa K J Crohns Colitis; 2013 Mar; 7(2):167-74. PubMed ID: 22626508 [TBL] [Abstract][Full Text] [Related]
14. Advances in the management of Crohn's disease: economic and clinical potential of infliximab. Hanauer SB; Cohen RD; Becker RV; Larson LR; Vreeland MG Clin Ther; 1998; 20(5):1009-28. PubMed ID: 9829451 [TBL] [Abstract][Full Text] [Related]
16. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204 [TBL] [Abstract][Full Text] [Related]
17. Infliximab for the treatment of Crohn's disease: review and indications for clinical use in Canada. Panaccione R; Can J Gastroenterol; 2001 Jun; 15(6):371-5. PubMed ID: 11429666 [TBL] [Abstract][Full Text] [Related]
18. Funding the new biologics--a health economic critique of the CCOHTA report: infliximab for the treatment of Crohn's disease. Mitton CR; Can J Gastroenterol; 2002 Dec; 16(12):873-6. PubMed ID: 12522479 [TBL] [Abstract][Full Text] [Related]
19. Costs of care for Crohn's disease following the introduction of infliximab: a single-centre UK experience. Sprakes MB; Ford AC; Suares NC; Warren L; Greer D; Donnellan CF; Jennings JS; Everett SM; Hamlin PJ Aliment Pharmacol Ther; 2010 Dec; 32(11-12):1357-63. PubMed ID: 21050238 [TBL] [Abstract][Full Text] [Related]
20. Costs of adalimumab versus infliximab as first-line biological therapy for luminal Crohn's disease. Choi GK; Collins SD; Greer DP; Warren L; Dowson G; Clark T; Hamlin PJ; Ford AC J Crohns Colitis; 2014 May; 8(5):375-83. PubMed ID: 24129316 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]